TY - JOUR A1 - Kiefer, Thomas A1 - Krahl, Dorothea A1 - Osthoff, Kathrin A1 - Thuss-Patience, Peter A1 - Bunse, Jörg A1 - Adam, Ulrich A1 - Jansen, Marc H. A1 - Ott, Rudolf A1 - Pfitzmann, Robert A1 - Pross, Matthias A1 - Kohlmann, Thomas A1 - Daeschlein, Georg A1 - Buhlert, Hermann A1 - Völler, Heinz A1 - Hirt, Carsten T1 - Importance of Pancreatic Enzyme Replacement Therapy after Surgery of Cancer of the Esophagus or the Esophagogastric Junction JF - Nutrition and cancer : an international journal N2 - After surgical treatment of cancer of the esophagus or the esophagogastric junction we observed steatorrhea, which is so far seldom reported. We analyzed all patients treated in our rehabilitation clinic between 2011 and 2014 and focused on the impact of surgery on digestion of fat. Reported steatorrhea was anamnestic, no pancreatic function test was made. Here we show the results from 51 patients. Twenty-three (45%) of the patients reported steatorrhea. Assuming decreased pancreatic function pancreatic enzyme replacement therapy (PERT) was started or modified during the rehabilitation stay (in the following called STEA(+)). These patients were compared with the patients without steatorrhea and without PERT (STEA(-)). Maximum weight loss between surgery and rehabilitation start was 18 kg in STEA(+) patient and 15.3 kg in STEA(-) patients. STEA(+) patients gained more weight under PERT during the rehabilitation phase (3 wk) than STEA(-) patients without PERT (+1.0 kg vs. -0.3 kg, P = 0.032). We report for the first time, that patients after cancer related esophageal surgery show anamnestic signs of exocrine pancreas insufficiency and need PERT to gain body weight. Y1 - 2017 U6 - https://doi.org/10.1080/01635581.2017.1374419 SN - 0163-5581 SN - 1532-7914 VL - 70 IS - 1 SP - 69 EP - 72 PB - Routledge, Taylor & Francis Group CY - Abingdon ER - TY - JOUR A1 - de Vera, Jean-Pierre Paul A1 - Böttger, Ute A1 - de la Torre Nötzel, Rosa A1 - Sanchez, Francisco J. A1 - Grunow, Dana A1 - Schmitz, Nicole A1 - Lange, Caroline A1 - Hübers, Heinz-Wilhelm A1 - Billi, Daniela A1 - Baque, Mickael A1 - Rettberg, Petra A1 - Rabbow, Elke A1 - Reitz, Günther A1 - Berger, Thomas A1 - Möller, Ralf A1 - Bohmeier, Maria A1 - Horneck, Gerda A1 - Westall, Frances A1 - Jänchen, Jochen A1 - Fritz, Jörg A1 - Meyer, Cornelia A1 - Onofri, Silvano A1 - Selbmann, Laura A1 - Zucconi, Laura A1 - Kozyrovska, Natalia A1 - Leya, Thomas A1 - Foing, Bernard A1 - Demets, Rene A1 - Cockell, Charles S. A1 - Bryce, Casey A1 - Wagner, Dirk A1 - Serrano, Paloma A1 - Edwards, Howell G. M. A1 - Joshi, Jasmin Radha A1 - Huwe, Björn A1 - Ehrenfreund, Pascale A1 - Elsaesser, Andreas A1 - Ott, Sieglinde A1 - Meessen, Joachim A1 - Feyh, Nina A1 - Szewzyk, Ulrich A1 - Jaumann, Ralf A1 - Spohn, Tilman T1 - Supporting Mars exploration BIOMEX in Low Earth Orbit and further astrobiological studies on the Moon using Raman and PanCam technology JF - Planetary and space science N2 - The Low Earth Orbit (LEO) experiment Biology and Mars Experiment (BIOMEX) is an interdisciplinary and international space research project selected by ESA. The experiment will be accommodated on the space exposure facility EXPOSE-R2 on the International Space Station (ISS) and is foreseen to be launched in 2013. The prime objective of BIOMEX is to measure to what extent biomolecules, such as pigments and cellular components, are resistant to and able to maintain their stability under space and Mars-like conditions. The results of BIOMEX will be relevant for space proven biosignature definition and for building a biosignature data base (e.g. the proposed creation of an international Raman library). The library will be highly relevant for future space missions such as the search for life on Mars. The secondary scientific objective is to analyze to what extent terrestrial extremophiles are able to survive in space and to determine which interactions between biological samples and selected minerals (including terrestrial, Moon- and Mars analogs) can be observed under space and Mars-like conditions. In this context, the Moon will be an additional platform for performing similar experiments with negligible magnetic shielding and higher solar and galactic irradiation compared to LEO. Using the Moon as an additional astrobiological exposure platform to complement ongoing astrobiological LEO investigations could thus enhance the chances of detecting organic traces of life on Mars. We present a lunar lander mission with two related objectives: a lunar lander equipped with Raman and PanCam instruments which can analyze the lunar surface and survey an astrobiological exposure platform. This dual use of testing mission technology together with geo- and astrobiological analyses will significantly increase the science return, and support the human preparation objectives. It will provide knowledge about the Moon's surface itself and, in addition, monitor the stability of life-markers, such as cells, cell components and pigments, in an extraterrestrial environment with much closer radiation properties to the surface of Mars. The combination of a Raman data base of these data together with data from LEO and space simulation experiments, will lead to further progress on the analysis and interpretation of data that we will obtain from future Moon and Mars exploration missions. KW - Moon KW - Mars KW - Low Earth Orbit KW - Astrobiology KW - Instrumentation KW - Spectroscopy KW - Biosignature Y1 - 2012 U6 - https://doi.org/10.1016/j.pss.2012.06.010 SN - 0032-0633 VL - 74 IS - 1 SP - 103 EP - 110 PB - Elsevier CY - Oxford ER - TY - JOUR A1 - van Egmond-Fröhlich, Andreas A1 - Mößle, Thomas A1 - Ahrens-Eipper, Sabine A1 - Schmid-Ott, Gerhard A1 - Hüllinghorst, Rolf A1 - Warschburger, Petra T1 - Übermässiger Medienkonsum von Kindern und Jugendlichen : Risiken für Psyche und Körper Y1 - 2007 UR - http://www.aerzteblatt.de/v4/archiv/artikel.asp?src=suche&p=&id=56968 ER - TY - JOUR A1 - Alter, Markus L. A1 - Ott, Ina M. A1 - von Websky, Karoline A1 - Tsuprykov, Oleg A1 - Sharkovska, Yuliya A1 - Krause-Relle, Katharina A1 - Raila, Jens A1 - Henze, Andrea A1 - Klein, Thomas A1 - Hocher, Berthold T1 - DPP-4 Inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy JF - Kidney & blood pressure research : official organ of the Gesellschaft für Nephrologie N2 - Background: The need for an improved treatment for diabetic nephropathy is greatest in patients who do not adequately respond to angiotensin II receptor blockers (ARBs). This study investigated the effect of the novel dipeptidyl peptidase-4 inhibitor linagliptin alone and in combination with the ARB telmisartan on the progression of diabetic nephropathy in diabetic endothelial nitric oxide synthase (eNOS) knockout mice. Methods: Sixty male eNOS knockout C57BL/6J mice were divided into four groups after receiving intraperitoneal high-dose streptozotocin: telmisartan (1 mg/kg), linagliptin (3 mg/kg), linagliptin + telmisartan (3 mg/kg + 1 mg/kg) and vehicle. Fourteen mice were used as non-diabetic controls. Results: After 12 weeks, urine and blood were obtained and blood pressure measured. Glucose concentrations were increased and similar in all diabetic groups. Telmisartan alone reduced systolic blood pressure by 5.9 mmHg versus diabetic controls (111.2 +/- 2.3 mmHg vs 117.1 +/- 2.2 mmHg; mean +/- SEM; P = 0.071). Combined treatment significantly reduced albuminuria compared with diabetic controls (71.7 +/- 15.3 mu g/24 h vs 170.8 +/- 34.2 mu g/24 h; P = 0.017), whereas the effects of single treatment with either telmisartan (97.8 +/- 26.4 mu g/24 h) or linagliptin (120.8 +/- 37.7 mu g/24 h) were not statistically significant. DPP-4 inhibition, alone and in combination, led to significantly lower plasma osteopontin levels compared with telmisartan alone. Histological analysis revealed reduced glomerulosclerosis after Linagliptin alone and in combination with telmisartan in comparison to non treated diabetic animals (p < 0.01 and p < 0.05). Kidney malonaldehyde immune-reactivity, a marker of oxidative stress, was significantly lower in animals treated with linagliptin. Conclusions: DPP-4 inhibition on top of ARB treatment significantly reduced urinary albumin excretion and oxidative stress in diabetic eNOS knockout mice. Linagliptin on top of an angiotensin II receptor blocker may offer a new therapeutic approach for patients with diabetic nephropathy. KW - Diabetic nephropathy KW - DPP-4 inhibitor KW - Linagliptin KW - Renin-angiotensin system Y1 - 2012 U6 - https://doi.org/10.1159/000341487 SN - 1420-4096 VL - 36 IS - 1 SP - 119 EP - 130 PB - Karger CY - Basel ER -